Utah osteopathic physician indicted over peptides from China allegedly sold to more than 200 patients
Short answer · as of 2026-10-06
DOCUMENTED, ALLEGATION ONLY. A U.S. Attorney’s Office release dated April 1, 2026 says Justin Bradley Watkins, a Utah-licensed osteopathic physician, was indicted on charges involving misbranded drugs from China. An indictment is an allegation, and the release says defendants are presumed innocent until proven guilty.
Attribution: Compiled from the U.S. Attorney’s Office, District of Utah, release of April 1, 2026, read directly. We did not find a later release, plea or disposition; we did not search court dockets. Counts and statutes are summarized as the release words them.
What happened
The U.S. Attorney’s Office for the District of Utah announced on April 1, 2026 that Justin Bradley Watkins, 39, a Utah-licensed osteopathic physician, was indicted for receipt in interstate commerce and delivery for pay of misbranded drugs with intent to defraud or mislead, and aiding and abetting.
DOJ alleges he obtained misbranded drugs from China, specifically peptides he knew were not FDA approved, and recommended, provided, delivered and sold them to more than 200 patients between February 2024 and April 2025.
The release lists the peptides as tirzepatide, semaglutide, retatrutide, cagrilinitide, BPC-157, TB500, ipamorelin, CJC 1295, GHK, GHK-CU and NAD+.
The case was investigated by FDA’s Office of Criminal Investigations and the Utah Division of Professional Licensing. The release gave April 22, 2026 for a court appearance before a magistrate judge in Salt Lake City.
The release says an indictment is merely an allegation and that all defendants are presumed innocent until proven guilty beyond a reasonable doubt in a court of law.
What we can verify
- The charges, period, peptide list, agencies and the presumption-of-innocence statement appear in the release itself.
- The release says the case concerns drugs the physician allegedly sold to his own patients.
What remains unknown
- The case number, the counts and any penalties: not in the release.
- Whether Watkins has entered a plea, whether a trial is set, and the case’s current status.
- Whether his license has been acted on.
- How the patients were identified.
Timeline
| Date / time | Event |
|---|---|
| 2024-02 to 2025-04 | Period DOJ alleges the misbranded peptides were obtained and supplied. |
| 2026-04-01 | DOJ announces the indictment. |
| 2026-04-22 | Court appearance scheduled before a magistrate judge, per the release; outcome not located. |
Participating agencies
| Agency | Reported role or presence |
|---|---|
| FDA Office of Criminal Investigations | Investigating agency, per the release. |
| Utah Division of Professional Licensing | Investigating agency, per the release. |
| U.S. Attorney’s Office, District of Utah | Prosecuting office; Assistant U.S. Attorney Mark Y. Hirata. |
Receipts
Company response
No company response located as of the publish date.
Why people care
This case concerns a physician and his patients, not a research-chemical website. It shows that DOJ treats clinic-supplied peptides from unapproved sources as a misbranding matter, as alleged. It is an indictment, and nothing here is a finding of guilt.
Terms explained
- What does “misbranded” mean in an FDA letter?
- Does a compounded drug need a prescription?
- How can peptides legally be obtained in the U.S.?
Corrections and update log
No corrections or updates. Request a correction.
Related stories
DOCUMENTED. A U.S. Attorney’s Office release dated July 23, 2026 says Brandon Piper of Gobles, Michigan was sentenced to 21 months in prison for conspiracy to introduce misbranded drugs with intent to defraud and mislead the FDA and consumers, in a case involving semaglutide and tirzepatide imported from China.
DOCUMENTED. U.S. Attorney’s Office releases describe three earlier prosecutions tied to peptide-type injectables: Tailor Made Compounding and Jeremy Delk (sentenced Feb. 24, 2021), Precision Peptides owner Gavin Burns Smith (May 9, 2016) and Adam F. Higdon (Oct. 15, 2013). None of the sentences in those releases was a federal prison term.
REPORTED. Local outlets say the U.S. Postal Inspection Service led a Sept. 23 search of Apex Waste Management in North Sioux City, SD, whose officers are tied in state records to Apex Peptides; none of those outlets reports FDA involvement or charges.